Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ctDNA Monitoring During Adjuvant Capecitabine in TNBC
NCT04768426Phase 2Recruiting
- Sponsor
- Stanford University
- Start
- Feb 2021
- Primary completion
- Nov 2026
- Modality
- DNA Intercalators/Alkylators, Irreversible Covalent Inhibitors, RNA-Targeting Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of capecitabine in triple-negative breast cancer (TNBC), sponsored by Stanford University. Started Feb 2021; status: recruiting.
02
Drugs
capecitabine
03
Conditions
triple-negative breast cancer (TNBC)
Beyond the preview
Go deeper on NCT04768426.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04768426.